Author: Bhimraj, Adarsh; Morgan, Rebecca L; Shumaker, Amy Hirsch; Lavergne, Valery; Baden, Lindsey; Cheng, Vincent Chi-Chung; Edwards, Kathryn M; Gandhi, Rajesh; Muller, William J; O’Horo, John C; Shoham, Shmuel; Murad, M Hassan; Mustafa, Reem A; Sultan, Shahnaz; Falck-Ytter, Yngve
Title: Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients with COVID-19 Cord-id: hwemigk7 Document date: 2020_4_27
ID: hwemigk7
Snippet: BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. METHODS: IDSA formed a multidisciplinary guidelin
Document: BACKGROUND: There are many pharmacologic therapies that are being used or considered for treatment of COVID-19. There is a need for frequently updated practice guidelines on their use, based on critical evaluation of rapidly emerging literature. OBJECTIVE: Develop evidence-based rapid guidelines intended to support patients, clinicians and other health-care professionals in their decisions about treatment and management of patients with COVID-19. METHODS: IDSA formed a multidisciplinary guideline panel of infectious disease clinicians, pharmacists, and methodologists with varied areas of expertise. Process followed a rapid recommendation checklist. The panel prioritized questions and outcomes. Then a systematic review of the peer-reviewed and grey literature was conducted. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess the certainty of evidence and make recommendations. RESULTS: The IDSA guideline panel agreed on 7 treatment recommendations and provided narrative summaries of other treatments undergoing evaluations. CONCLUSIONS: The panel expressed the overarching goal that patients be recruited into ongoing trials, which would provide much needed evidence on the efficacy and safety of various therapies for COVID-19, given that we could not make a determination whether the benefits outweigh harms for most treatments.
Search related documents:
Co phrase search for related documents- abdominal discomfort and long term short term: 1, 2
- abstract title and academic journal: 1, 2
- abstract title and activity show: 1
- abstract title and acute ards respiratory distress syndrome: 1
- abstract title and additional grey literature: 1
- abstract title and additional guideline: 1
- abstract title and additional term: 1
- abstract title and address research question: 1
- abstract title and long term short term: 1, 2
- abstract title and lopinavir ritonavir: 1, 2
- abstract title and low certainty: 1, 2, 3, 4
- abstract title and lung disease: 1
Co phrase search for related documents, hyperlinks ordered by date